ClinicalTrials.gov
public full text
Public Domain
A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC
This is a Phase 1b, open-label, multicentre study of AZD6094 in combination with gefitinib in patients with epidermal growth factor receptor (EGFR) mutation positive (m+) and progressed on EGFR Tyrosine kinase inhibitor (TKI) treatment.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- GABI-ProTect, Identifizierung und Charakterisierung neuer chemoprotektiver Substanzen für Pflanzenschutz und Medizin, Teilvorhaben C : Laufzeit: 01.09.2007 - 31.12.2010 ; Schlussbericht zum GABI-FUTURE Verbundvorhaben#129621
- An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" Vaccine Against COVID-19#855803
- Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients#1153351
- Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age#1059145
- A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine#1009225
Record · ID 886923
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive